

CORCEPT THERAPEUTICS INC  
 Form 4  
 August 05, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**WILSON JAMES N**

2. Issuer Name and Ticker or Trading Symbol  
**CORCEPT THERAPEUTICS INC [CORT]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
**08/03/2015**

Director  10% Owner  
 Officer (give title below)  Other (specify below)

**C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE**

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**MENLO PARK, CA 94025**

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (A) or (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	07/22/2015		G <sup>(1)</sup>	V 1,000 D \$ 0	1,578,396	I	James N. Wilson and Pamela D. Wilson Trust
Common stock	08/03/2015		M	3,000 A \$ 1.51	1,581,396	I	James N. Wilson and Pamela D.

Common stock	08/03/2015	S	3,000	D	\$ 4.968 <u>(2)</u>	1,578,396	I	Wilson Trust James N. Wilson and Pamela D. Wilson Trust
Common stock	08/04/2015	M	2,900	A	\$ 1.51	1,581,296	I	James N. Wilson and Pamela D. Wilson Trust
Common stock	08/04/2015	S	2,900	D	\$ 4.9 <u>(2)</u>	1,578,396	I	James N. Wilson and Pamela D. Wilson Trust
Common stock	08/05/2015	M	4,100	A	\$ 1.51	1,582,496	I	James N. Wilson and Pamela D. Wilson Trust
Common stock	08/05/2015	S	4,100	D	\$ 4.9 <u>(2)</u>	1,578,396	I	James N. Wilson and Pamela D. Wilson Trust
Common stock	08/05/2015 <sup>(3)</sup>	S <sup>(3)</sup>	0	D <sup>(3)</sup>	\$ 0	901,067	I	James and Pamela Wilson Family Partners

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Title and Amount of Underlying Securities (Instr. 3 and 4)
Stock option	\$ 1.51	08/03/2015		M	3,000	<u>(4)</u> 05/18/2017	Common stock	3,000
Stock option	\$ 1.51	08/04/2015		M	2,900	<u>(4)</u> 05/18/2017	Common stock	2,900
Stock option	\$ 1.51	08/05/2015		M	4,100	<u>(4)</u> 05/18/2017	Common stock	4,100

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
WILSON JAMES N C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025	X			

## Signatures

/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated  
attorney-in-fact

08/05/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares distributed to family members of the Reporting Person.
- (2) Represents the weighted average sale price for the entire number of shares sold.
- (3) Not applicable as the line item was included to show all other indirect holdings of the Reporting Person.
- (4) Fully exerciseable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.